Elanco and Bayer deal taps into emerging trends shaping a modern animal health sector

摘要

Elanco's pending purchase of Bayer Animal Health is a deal that capitalizes on industry trends that have emerged this year, claims chief executive Jeff Simmons.Waves of consolidation in the industry are creating firms with similar offerings, differentiated only by specialties such as vaccines, medicated feed additives or antiparasitics. For example, Zoetis has a robust anti-infective and pharmaceutical pipeline - setting it apart from others. Elanco specializes in productivity enhancers and, with the Bayer acquisition, will harness a focus on parasiticides.